You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020112013
Dec 20201607
Jan 20212506
Feb 202136010
Mar 20214007
Apr 20213005
May 202112010
Jun 20210011
Jul 2021005
Aug 2021006
Sep 2021005
Oct 202140021
Nov 202128017
Dec 20214002
Jan 202226013
Feb 20224603
Mar 202234010
Apr 20224604
May 20224605
Jun 20221402
Jul 20223803
Aug 20222808
Sep 20222406
Oct 20221401
Nov 20222603
Dec 20221601
Jan 20232200
Feb 20232801
Mar 20231602
Apr 20233605
May 20233205
Jun 20231202
Jul 20231609
Aug 20231402
Sep 20232003
Oct 20232802
Nov 20232803
Dec 20234202
Jan 20241400
Feb 20242000
Mar 20241602
Apr 20243204
May 20242001
Jun 20242404
Jul 20249000
Aug 20242001
Sep 20242202
Oct 20242600
Nov 20242004
Dec 20241604
Jan 20252204
Feb 2025200
Mar 2025001
Apr 2025003
May 2025006
Jun 2025003
Total13750259